tiprankstipranks
Trending News
More News >
Mabion SA (DE:272)
FRANKFURT:272
Germany Market
Advertisement

Mabion SA (272) Drug Pipeline

Compare
0 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Mabioncd20 (Candidate Biosimilar To Rituximab), Mabthera®, Rituxan®
Rheumatoid Arthritis
Phase III
Withdrawn
MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis
Dec 02, 2020
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Diffuse Large B-Cell Lymphoma
Phase III
Completed
MabionCD20 Compared to MabThera in Lymphoma Patients
Nov 12, 2015
Rituximab
Rheumatoid Arthritis
Phase III
Completed
MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis
Jun 09, 2015

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Mabion SA (272) have in its pipeline
      272 is currently developing the following drugs: Mabioncd20 (Candidate Biosimilar To Rituximab), Mabthera®, Rituxan®, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis